Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine for REM sleep behavior disorder and hallucinations in Parkinsonism
2009-012071-10Phase 2Completed
- Sponsor
- Policlinico Gemelli
- Start
- May 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of rivastigmine in parkinsonism and REM sleep behavior disorder (RBD), sponsored by Policlinico Gemelli. Primary endpoints: Clinical questionnaire assessment of RBD and hallucinations and 24-hour EEG / polysomnography. Started May 2009; status: completed.
02
Drugs
rivastigmine
03
Conditions
parkinsonismREM sleep behavior disorder (RBD)
Beyond the preview
Go deeper on 2009-012071-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012071-10.